Debabrata Chakravarti
Has grant
Professor and associate Chief, Div of Reprod Sci in Med
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Debabrata Chakravarti is an Associate Professor at Northwestern University Feinberg School of Medicine, located in the United States. His research primarily focuses on mitochondrial metabolism and its implications for cancer therapy, with recent articles addressing impaired mitochondrial metabolism as a significant vulnerability in the context of MYC inhibitors.
Recent Grants
Grant: Close
Integrative Genomics, Epigenomics and Bioinformatics Analyses of Human Uterine Fibroids
Open Date: 2016-09-16
Close Date: 2021-06-30
Grant: Close
Probing Mediator 12 function in uterine fibroids
Open Date: 2015-08-20
Close Date: 2017-07-31
Grant: Close
Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer
Open Date: 2015-07-01
Close Date: 2020-06-30
Grant: Close
Regulatory Mechanisms in Hormonal and Transcriptional Signaling
Open Date: 2010-07-05
Close Date: 2012-06-30
Grant: Close
Role of a Novel THAP-Family Protein in Transcription and Cancer Cell Function
Open Date: 2009-09-01
Close Date: 2014-07-31
Articles (2)
MYC is a key driver in many aggressive and therapy-resistant cancers. We have developed and characterized a small-molecule MYC inhibitor named MYCi975. To uncover combination strategies for MYC inhibitors, we conducted a genome-wide CRISPR screen using MYCi975. This screen revealed a notable synthetic lethality when MYC inhibition was paired with disruption of mitochondrial complex I components, but not other complexes. Mechanistically, MYC inhibition reduced oxidative phosphorylation and glycolysis, triggering a compensatory up-regulation of complex I genes. Consequently, genetic or pharmacological targeting of complex I sensitized tumors to MYCi975 treatment, leading to increased purine catabolism and infiltration of CD8 + T cells and macrophages into tumors. Additionally, a wide range of tumor cells with lower complex I expression showed increased MYC dependency. These results indicate that metabolic adaptation to MYC inhibition exposes a targetable weakness at complex I and provide a rational strategy for combination therapy with emerging MYC inhibitors.
Year:
2025
MYC regulates multiple gene programs, raising questions about the potential selectivity and downstream transcriptional consequences of MYC inhibitors as cancer therapeutics. Here, we examined the effect of a small-molecule MYC inhibitor, MYCi975, on the MYC/MAX cistromes, epigenome, transcriptome, and tumorigenesis. Integrating these data revealed three major classes of MYCi975-modulated gene targets: type 1 (down-regulated), type 2 (up-regulated), and type 3 (unaltered). While cell cycle and signal transduction pathways were heavily targeted by MYCi, RNA biogenesis and core transcriptional pathway genes were spared. MYCi975 altered chromatin binding of MYC and the MYC network family proteins, and chromatin accessibility and H3K27 acetylation alterations revealed MYCi975 suppression of MYC-regulated lineage factors AR/ARv7, FOXA1, and FOXM1. Consequently, MYCi975 synergistically sensitized resistant prostate cancer cells to enzalutamide and estrogen receptor–positive breast cancer cells to 4-hydroxytamoxifen. Our results demonstrate that MYCi975 selectively inhibits MYC target gene expression and provide a mechanistic rationale for potential combination therapies.
Year:
2022
Collaborators (2)
Sarki A. Abdulkadir
Northwestern University Feinberg School of Medicine
Gary E. Schiltz
Northwestern University
Make your next move.
Prepare your application
Review drafts before you send them.